PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Moolec Science SA Warrant (MLECW)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

Sector

Healthcare

IPO Date

Jan 3, 2023

Highlights

Total Revenue (TTM)

$5.19M

Gross Profit (TTM)

$34.87K

EBITDA (TTM)

-$1.70M

Year Range

$0.02 - $0.09

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Moolec Science SA Warrant, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%SeptemberOctoberNovemberDecember2025February
-14.60%
9.06%
MLECW (Moolec Science SA Warrant)
Benchmark (^GSPC)

Returns By Period

Moolec Science SA Warrant had a return of 56.69% year-to-date (YTD) and -26.57% in the last 12 months.


MLECW

YTD

56.69%

1M

27.56%

6M

-14.59%

1Y

-26.57%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.22%

1M

2.22%

6M

9.51%

1Y

22.46%

5Y*

12.74%

10Y*

11.29%

*Annualized

Monthly Returns

The table below presents the monthly returns of MLECW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202523.23%56.69%
202481.36%43.86%-51.05%87.54%13.85%-16.67%30.00%-46.00%13.96%-0.25%10.03%-42.14%15.45%
2023-28.62%33.42%-43.90%-18.98%-14.41%2.70%-13.39%-6.79%-45.58%-28.49%19.52%-26.67%-89.52%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of MLECW is 50, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of MLECW is 5050
Overall Rank
The Sharpe Ratio Rank of MLECW is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of MLECW is 9191
Sortino Ratio Rank
The Omega Ratio Rank of MLECW is 8989
Omega Ratio Rank
The Calmar Ratio Rank of MLECW is 1313
Calmar Ratio Rank
The Martin Ratio Rank of MLECW is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Moolec Science SA Warrant (MLECW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for MLECW, currently valued at -0.13, compared to the broader market-2.000.002.004.00-0.131.77
The chart of Sortino ratio for MLECW, currently valued at 3.03, compared to the broader market-6.00-4.00-2.000.002.004.006.003.032.39
The chart of Omega ratio for MLECW, currently valued at 1.38, compared to the broader market0.501.001.502.001.381.32
The chart of Calmar ratio for MLECW, currently valued at -0.57, compared to the broader market0.002.004.006.00-0.572.66
The chart of Martin ratio for MLECW, currently valued at -1.05, compared to the broader market0.0010.0020.0030.00-1.0510.85
MLECW
^GSPC

The current Moolec Science SA Warrant Sharpe ratio is -0.13. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Moolec Science SA Warrant with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.13
1.77
MLECW (Moolec Science SA Warrant)
Benchmark (^GSPC)

Dividends

Dividend History


Moolec Science SA Warrant doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-81.91%
0
MLECW (Moolec Science SA Warrant)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Moolec Science SA Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Moolec Science SA Warrant was 92.23%, occurring on Dec 26, 2023. The portfolio has not yet recovered.

The current Moolec Science SA Warrant drawdown is 81.91%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.23%Feb 28, 2023139Dec 26, 2023
-46%Jan 4, 202317Jan 27, 202313Feb 27, 202330

Volatility

Volatility Chart

The current Moolec Science SA Warrant volatility is 73.38%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%SeptemberOctoberNovemberDecember2025February
73.38%
3.19%
MLECW (Moolec Science SA Warrant)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Moolec Science SA Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Moolec Science SA Warrant.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab